These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 1281446

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for non-small cell lung cancer.
    Mori K, Saitoh Y, Tominaga K.
    Eur J Cancer; 1993; 29A(5):677-80. PubMed ID: 8385969
    [Abstract] [Full Text] [Related]

  • 4. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.).
    Gridelli C, Perrone F, Palmeri S, D'Aprile M, Cognetti F, Rossi A, Gebbia V, Pepe R, Veltri E, Airoma G, Russo A, Incoronato P, Scinto AF, Palazzolo G, Natali M, Leonardi V, Gallo C, De Placido S, Bianco AR.
    Ann Oncol; 1996 Oct; 7(8):821-6. PubMed ID: 8922196
    [Abstract] [Full Text] [Related]

  • 5. [Effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with lung cancer].
    Ohnoshi T, Ueoka H, Kodani T, Kamei H, Kimura I.
    Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 2):911-8. PubMed ID: 1693062
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of recombinant human granulocyte-macrophage colony-stimulating factor for chemotherapy-induced leukopenia in patients with non-small-cell lung cancer.
    Eguchi K, Kabe J, Kudo S, Mano K, Morinari H, Nakada K, Noda K, Saito Y, Tanaka T, Uzawa T.
    Cancer Chemother Pharmacol; 1994 Apr; 34(1):37-43. PubMed ID: 8174201
    [Abstract] [Full Text] [Related]

  • 7. [Effect of timing of granulocyte-colony stimulating factor administration on leukopenia induced by systemic chemotherapy in patients with non-small-cell lung cancer--multi-center randomized crossover study].
    Katakami N, Hasegawa T, Umeda B, Adachi S, Ishii N, Takada Y, Tsubota N, Nakano K, Tamura R, Nakai H.
    Nihon Kyobu Shikkan Gakkai Zasshi; 1996 May; 34(5):520-8. PubMed ID: 8753109
    [Abstract] [Full Text] [Related]

  • 8. Double-cycle high-dose chemotherapy with peripheral blood stem cells and hematopoietic growth factor support in patients with advanced solid tumor. A pilot study by the Hong Kong Biotherapy Group.
    Yeung AW, Pang YK, Tsang YC, Wong SW.
    Cancer; 1994 Apr 01; 73(7):1960-70. PubMed ID: 7511042
    [Abstract] [Full Text] [Related]

  • 9. Moderate dose-intensive chemotherapy for patients with non-small cell lung cancer: randomized trial, can it improve survival of patients with good performance status?
    Masutani M, Tsujino I, Fujie T, Yamaguchi M, Miyagi K, Yano T, Takahashi N, Koya Y, Horie T.
    Oncol Rep; 1999 Apr 01; 6(5):1045-50. PubMed ID: 10425301
    [Abstract] [Full Text] [Related]

  • 10. A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer.
    Rosell R, Abad-Esteve A, Moreno I, Barnadas A, Carles J, Fernandez C, Ribelles N, Culubret M.
    Cancer; 1990 Apr 15; 65(8):1692-9. PubMed ID: 2156597
    [Abstract] [Full Text] [Related]

  • 11. Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).
    Crinò L, Clerici M, Figoli F, Carlini P, Ceci G, Cortesi E, Carpi A, Santini A, Di Costanzo F, Boni C.
    Ann Oncol; 1995 Apr 15; 6(4):347-53. PubMed ID: 7619749
    [Abstract] [Full Text] [Related]

  • 12. Phase II study of a closely spaced ifosfamide--cisplatin schedule with the addition of G-CSF in advanced non-small-cell lung cancer and malignant melanoma.
    Planting AS, de Wit R, van der Burg ME, Stoter G, Verweij J.
    Ann Oncol; 1996 Dec 15; 7(10):1080-2. PubMed ID: 9037369
    [Abstract] [Full Text] [Related]

  • 13. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
    Recchia F, Sica G, De Filippis S, Rosselli M, Saggio G, Guerriero G, Pompili P, Rea S.
    Anticancer Res; 2000 Dec 15; 20(3B):1985-90. PubMed ID: 10928138
    [Abstract] [Full Text] [Related]

  • 14. A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer.
    Mehdi SA, Perry MC, Herndon JE, Crawford J, Young R, Graziano SL.
    J Interferon Cytokine Res; 1998 Aug 15; 18(8):623-7. PubMed ID: 9726444
    [Abstract] [Full Text] [Related]

  • 15. Prophylactic administration of granulocyte colony-stimulating factor when monocytopenia appears lessens neutropenia caused by chemotherapy for lung cancer.
    Oshita F, Yamada K, Nomura I, Tanaka G, Ikehara M, Noda K.
    Am J Clin Oncol; 2000 Jun 15; 23(3):278-82. PubMed ID: 10857893
    [Abstract] [Full Text] [Related]

  • 16. Superiority of three-drug combination chemotherapy versus cisplatin-etoposide in advanced non-small cell lung cancer: a randomized trial by the Italian Oncology Group for Clinical Research.
    Crinò L, Clerici M, Figoli F, Barduagni M, Carlini P, Ceci G, Cortesi E, Carpi A, Santini A, Di Costanzo F.
    Lung Cancer; 1995 Apr 15; 12 Suppl 1():S125-32. PubMed ID: 7551920
    [Abstract] [Full Text] [Related]

  • 17. Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study. Italian Lung Cancer Task Force (FONICAP).
    Baldini E, Tibaldi C, Ardizzoni A, Salvati F, Antilli A, Portalone L, Barbera S, Romano F, De Marinis F, Migliorino MR, Noseda MA, Borghini U, Crippa M, Ferrara G, Raimondi M, Fioretti M, Bandera M, Pennucci MC, Galeasso G, Cacciani GC, Lepidini G, Sunseri G, Lanfranco C, Rinaldi M, Rosso R.
    Br J Cancer; 1998 Jun 15; 77(12):2367-70. PubMed ID: 9649160
    [Abstract] [Full Text] [Related]

  • 18. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
    Yang S, Shi YK, Liu P, Han XH, He XH, Cai YM, Chen ZM.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun 15; 28(3):339-44. PubMed ID: 16900629
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of cisplatin as a 5-day continuous infusion with vindesine plus recombinant human granulocyte-colony-stimulating factor in the treatment of advanced non-small-cell lung cancer.
    Saito Y, Mori K, Tominaga K, Yokoi K, Miyazawa N.
    Cancer Chemother Pharmacol; 1992 Jun 15; 31(2):81-4. PubMed ID: 1280537
    [Abstract] [Full Text] [Related]

  • 20. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
    Shi YK, He XH, Yang S, Wang HQ, Jiang ZF, Zhu YZ, Ke XY, Zhang Y, Liu YP, Zhang WJ, Wang Z, Shi QZ, Xie XD, Zhang HL, Wang JJ, Luo DY, Zheng QS, Sun RY.
    Zhonghua Yi Xue Za Zhi; 2006 Dec 26; 86(48):3414-9. PubMed ID: 17313855
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.